Med24
overweight-obesity 31. 7. 2026 • 2 min read • The world journal of men's health

Adiposity Change Patterns and Prostate Cancer Risk: Age- and Smoking-Specific Associations in 1,332,372 Korean Males

Purpose Evidence linking body mass index (BMI) change to prostate cancer risk remains inconsistent despite known associations between adiposity and prostate carcinogenesis. Materials and methods We conducted a population-based cohort study of 1,332,372 Korean males who completed health examinations in 2009 and 2013...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A population-based cohort study examined the relationship between changes in body mass index (BMI) and prostate cancer risk in 1,332,372 Korean males. The study followed participants from 2009 to 2017, classifying BMI using Asia-Pacific criteria and defining BMI change into 25 groups. Prostate cancer diagnoses were confirmed using ICD-10 codes.

Study Design and Population

The analysis assessed adjusted hazard ratios and 95% confidence intervals to determine associations between BMI trajectories and cancer risk, controlling for demographic, lifestyle, and comorbidity factors. Over a period of 12.7 million person-years, 9,147 prostate cancers were identified.

Sponsored content

Key Clinical Findings

Remaining underweight or transitioning from underweight to normal BMI was associated with a lower risk. Persistent overweight, persistent obesity I, and transitioning from overweight to obesity I were linked to increased risk. Among males with obesity I, weight loss to normal BMI was associated with a reduced risk compared to persistent obesity I. The study found that persistent obesity II (≥30 kg/m²) was associated with lower risk among males. These findings suggest that the impact of longitudinal adiposity patterns varies by smoking status and age, supporting personalized, lifestage-specific prevention emphasizing weight management and lifestyle modification.

Original Scientific Source
The world journal of men's health
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement